ShadowGraph
Start free trial
SEC filings · customer concentration · MCK

Who depends on McKesson

12 listed suppliers report McKesson as a customer worth 10% or more of their revenue, led by Coherus Oncology at 43%.

0major customers now
—of revenue from them
12listed suppliers depending on it
2011–2026years covered
Free

Get an email when McKesson's customer concentration changes

When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.

We only use your address for this watch. Double opt-in, see our privacy notice.

Suppliers that depend on McKesson

Listed companies whose annual report names McKesson as a customer worth 10% or more of their revenue. If McKesson cuts orders or switches supplier, these are the companies that feel it.

SupplierIts revenue from this companyChange vs prior yearHistoryLatest filing
Coherus OncologyCHRS43%from 43%FY 2019: 42%FY 2020: 38%FY 2021: 39%FY 2022: 38%FY 2023: 40%FY 2024: 43%FY 2025: 43%7 yearsFY 2025 · filed 9 Mar 2026
ADC TherapeuticsADCT39%from 41%FY 2022: 41%FY 2023: 40%FY 2024: 41%FY 2025: 39%4 yearsFY 2025 · filed 10 Mar 2026
Bristol Myers SquibbBMY36%from 34%FY 2019: 26%FY 2020: 31%FY 2021: 32%FY 2022: 32%FY 2023: 33%FY 2024: 34%FY 2025: 36%7 yearsFY 2025 · filed 11 Feb 2026
AlkermesALKS31%▲ from 25%FY 2020: 14%FY 2021: 13%FY 2022: 16%FY 2023: 14%FY 2024: 25%FY 2025: 31%6 yearsFY 2025 · filed 25 Feb 2026
PfizerPFE25%from 23%FY 2018: 13%FY 2019: 15%FY 2020: 16%FY 2021: 9%FY 2022: 8%FY 2023: 16%FY 2024: 23%FY 2025: 25%8 yearsFY 2025 · filed 26 Feb 2026
Gilead SciencesGILD24%from 23%FY 2016: 22%FY 2017: 23%FY 2018: 21%FY 2019: 22%FY 2020: 20%FY 2021: 20%FY 2022: 20%FY 2023: 24%FY 2024: 23%FY 2025: 24%10 yearsFY 2025 · filed 24 Feb 2026
Amphastar PharmaceuticalsAMPH24%from 25%FY 2012: 27%FY 2013: 26%FY 2014: 22%FY 2015: 22%FY 2016: 21%FY 2017: 27%FY 2018: 27%FY 2019: 25%FY 2020: 22%FY 2021: 21%FY 2022: 22%FY 2023: 25%FY 2024: 25%FY 2025: 24%14 yearsFY 2025 · filed 26 Feb 2026
ExelixisEXEL19%from 16%FY 2016: 7%FY 2017: 11%FY 2018: 12%FY 2020: 12%FY 2021: 14%FY 2022: 17%FY 2023: 17%FY 2025: 16%FY 2026: 19%10 yearsFY 2026 · filed 10 Feb 2026
ArdelyxARDX18%from 14%FY 2022: 9%FY 2023: 16%FY 2024: 14%FY 2025: 18%4 yearsFY 2025 · filed 19 Feb 2026
Bausch Health CompaniesBHC16%from 15%FY 2011: 23%FY 2012: 20%FY 2013: 19%FY 2014: 17%FY 2015: 20%FY 2016: 21%FY 2017: 19%FY 2018: 18%FY 2019: 17%FY 2020: 17%FY 2021: 16%FY 2022: 15%FY 2023: 15%FY 2024: 15%FY 2025: 16%15 yearsFY 2025 · filed 19 Feb 2026
Jazz PharmaceuticalsJAZZ10%from 12%FY 2015: 7%FY 2016: 15%FY 2017: 16%FY 2018: 17%FY 2019: 14%FY 2020: 12%FY 2021: 12%FY 2022: 11%FY 2023: 11%FY 2024: 12%FY 2025: 10%11 yearsFY 2025 · filed 24 Feb 2026
Bausch & LombBLCO10%from 10%FY 2024: 10%FY 2025: 10%2 yearsFY 2025 · filed 18 Feb 2026

Formerly disclosed

SupplierIts revenue from this companyChange vs prior yearHistoryLatest filing
Akebia TherapeuticsAKBA12%last FY 2024FY 2020: 11%FY 2021: 13%FY 2023: 11%FY 2024: 12%4 yearsFY 2024 · filed 26 Feb 2026
ViatrisVTRS10%last FY 2023FY 2019: 15%FY 2020: 13%FY 2021: 9%FY 2022: 11%FY 2023: 10%5 yearsFY 2023 · filed 26 Feb 2026

About this data

US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.

All companies · Latest dependency shifts · Bulk data and API